Aeterna Zentaris Inc. (AEZS)
NASDAQ (CM) NASDAQ (CM) Primary Summary
AEZS Chart
Aeterna Zentaris Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 119.03 | $3.81 | $0.04 | -$3.77 | -98.95% |
Aeterna Zentaris Inc. (AEZS) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Aeterna Zentaris Inc. Profile
| - Industry | - Sector | Gilles R. Gagnon CEO | NASDAQ (CM) Exchange | 007975402 CUSIP |
| US Country | 12 Employees | - Last Dividend | 5 Oct 2012 Last Split | - IPO Date |
Overview
Aeterna Zentaris Inc., positioned as a specialty biopharmaceutical enterprise, undertakes the development and commercialization of diagnostic tests and therapeutics. The company's research and product development spans across multiple countries including Canada, Switzerland, Ireland, Denmark, Germany, the United States, and others on a global scale. With its establishment dating back to 1990 and headquarters in Toronto, Canada, Aeterna Zentaris focuses on addressing critical health issues primarily within the realms of endocrinology and oncology. The collaboration with academic and commercial partners showcases its commitment to advancing healthcare solutions through innovative therapies and diagnostic tools.
Products and Services
- Macrilen (macimorelin)
- AEZS-150
- AEZS-130 (Preclinical Stage for ALS)
- Licensing and Research Agreements
- Commercialization and Distribution Agreements
An orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist, Macrilen stands as the company's flagship product. It is designed to stimulate growth hormone secretion by targeting the GHSR-1a, facilitating the diagnosis of adult and childhood-onset growth hormone deficiency. Beyond diagnostics, the drug explores therapeutic applications in endocrinology and oncology.
Aeterna Zentaris is evolving AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide currently in the preclinical trial stage. This investigational therapy is being developed for the treatment of chronic hypoparathyroidism, a condition that demands new and effective therapeutic approaches.
AEZS-130 is undergoing preclinical trial targeting the treatment of amyotrophic lateral sclerosis (ALS), demonstrating the company's commitment to addressing complex neurological disorders.
Aeterna Zentaris has entered into significant research and licensing agreements with institutions such as the University of Wuerzburg to foster the development and commercialization of AIM biologicals for neuromyelitis optica spectrum disorder. Similarly, initiatives are underway for the pre-clinical development of treatments for Parkinson’s disease, showcasing a broad research spectrum from neurology to endocrinology.
Strategic agreements with entities like Consilient Health Ltd., NK MEDITECH Ltd., and Er-Kim Pharmaceuticals Bulgaria Eood are instrumental for the development and commercialization of macimorelin. These partnerships enable the expansion of macimorelin's global footprint, making it accessible for the diagnosis of growth hormone deficiency across age groups. Additionally, a collaborative effort with The University of Sheffield in the United Kingdom is in place for developing parathyroid hormone fusion polypeptides, aimed at treating chronic hypoparathyroidism.
